|
Programmed cell death-1 ligand (PD-L1) expression on circulating CD45(-) cells is an independent prognostic factor for overall survival in patients (Pts) with lung cancer in a prospective, multicenter cohort. |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Epic Sciences |
|
|
Stock and Other Ownership Interests - Epic Sciences |
Consulting or Advisory Role - AstraZeneca; Genoptix; Heat Biologics; Pfizer |
Speakers' Bureau - Genentech; Novartis |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
|
Stock and Other Ownership Interests - Epic Sciences |
|
|
No Relationships to Disclose |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Stock and Other Ownership Interests - Epic Sciences |
Consulting or Advisory Role - Epic Sciences |
Patents, Royalties, Other Intellectual Property - Epic Sciences |
|
|
Employment - Epic Sciences |
Leadership - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
Patents, Royalties, Other Intellectual Property - Patents Pending |